drugset / Trial / NCT03828448
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2, open label study to assess umbralisib in combination with ublituximab in participants with treatment naïve Follicular Lymphoma (FL) and Small Lymphocytic Lymphoma (SLL).
Timeline
- Start
- 2019-07-10
- Primary completion
- 2022-05-16
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ublituximab | Monoclonal antibody | 900 mg | Intravenous |
| Subject | Umbralisib | Small molecule | 800 mg | Oral |